Generic Spinraza Availability
Last updated on Dec 12, 2024.
Spinraza is a brand name of nusinersen, approved by the FDA in the following formulation(s):
SPINRAZA (nusinersen sodium - solution;intrathecal)
-
Manufacturer: BIOGEN IDEC
Approval date: December 23, 2016
Strength(s): EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) [RLD]
Has a generic version of Spinraza been approved?
No. There is currently no therapeutically equivalent version of Spinraza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spinraza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
Patent 10,266,822
Issued: April 23, 2019
Inventor(s): Singh Ravindra N. & Singh Natalia N. & Singh Nirmal K. & Androphy Elliot J.
Assignee(s): UNIVERSITY OF MASSACHUSETTSThe present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).
Patent expiration dates:
- December 5, 2025✓
- December 5, 2025✓
- December 5, 2025✓
- December 5, 2025
-
Methods for treating spinal muscular atrophy
Patent 10,436,802
Issued: October 8, 2019
Inventor(s): Rigo Frank & Bishop Katherine M.
Assignee(s): Biogen MA Inc.Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy. Also provided are kits for detecting the amount of SMN protein in a sample of cerebrospinal fluid.
Patent expiration dates:
- September 11, 2035✓
- September 11, 2035✓
- September 11, 2035✓
- September 11, 2035✓
- September 11, 2035✓
- September 11, 2035✓
- September 11, 2035
-
Patent 12,013,403
Patent expiration dates:
- March 4, 2036✓
- March 4, 2036✓
- March 4, 2036✓
- March 4, 2036✓
- March 4, 2036✓
- March 4, 2036✓
- March 4, 2036
-
Patent 7,838,657
Patent expiration dates:
- July 11, 2027✓
- July 11, 2027
-
SMN2
Patent 8,110,560
Issued: February 7, 2012
Inventor(s): Singh Ravindra N. & Singh Natalia N. & Singh Nirmal K. & Androphy Elliot J.
Assignee(s): University of MassachusettsThe present invention is directed to methods and compositions capable of blocking the inhibitory effect of a newly-identified intronic inhibitory sequence element, named ISS-N1 (for “intronic splicing silencer”), located in the SMN2 gene. The compositions and methods of the instant invention include oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target the SMN2 ISS-N1 site in the SMN2 pre-mRNA, thereby modulating the splicing of SMN2 pre-mRNA to include exon 7 in the processed transcript. The ISS-N1 blocking agents of the invention cause elevated expression of SMN protein, thus compensating for the loss of SMN protein expression commonly observed in subjects with spinal muscular atrophy (SMA).
Patent expiration dates:
- December 5, 2025✓
- December 5, 2025✓
- December 5, 2025✓
- December 5, 2025
-
Compositions and methods for modulation of SMN2 splicing
Patent 8,361,977
Issued: January 29, 2013
Inventor(s): Baker Brenda F. & Krainer Adrian R. & Hua Yimin
Assignee(s): Isis Pharmaceuticals, Inc.Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a cell, tissue or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Patent expiration dates:
- December 23, 2030✓✓
- December 23, 2030
-
Compositions and methods for modulation of SMN2 splicing in a subject
Patent 8,980,853
Issued: March 17, 2015
Inventor(s): Bennett C. Frank & Hung Gene & Rigo Frank & Krainer Adrian R. & Hua Yimin & Passini Marco A. & Shihabuddin Lamya & Cheng Seng H. & Klinger Katherine W.Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Patent expiration dates:
- November 24, 2030✓
- November 24, 2030
-
Compositions and methods for modulation of SMN2 splicing in a subject
Patent 9,717,750
Issued: August 1, 2017
Inventor(s): Bennett C. Frank & Hung Gene & Rigo Frank & Krainer Adrian R. & Hua Yimin & Passini Marco A. & Shihabuddin Lamya & Cheng Seng H. & Klinger Katherine W.Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Patent expiration dates:
- June 17, 2030✓
- June 17, 2030✓
- June 17, 2030✓
- June 17, 2030✓
- June 17, 2030
-
Compositions and methods for modulation of SMN2 splicing in a subject
Patent 9,926,559
Issued: March 27, 2018
Inventor(s): Bennett C. Frank & Hung Gene & Rigo Frank
Assignee(s): Biogen MA Inc.Disclosed herein are compounds, compositions and methods for modulating splicing of SMN2 mRNA in a subject. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders, including spinal muscular atrophy.
Patent expiration dates:
- January 9, 2034✓
- January 9, 2034
More about Spinraza (nusinersen)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous uncategorized agents
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.